Search

Displaying results 3991 - 4000 of 7059 in total
  1. Drug

    Ganciclovir

    go.drugbank.com/drugs/DB01004
    ApprovedInvestigational

    An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

    Categories: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
  2. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    [L10241] In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs). … Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Pentoxyverine

    go.drugbank.com/drugs/DB11186
    ApprovedWithdrawn

    Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties. … The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate.[L43942] Other forms of pentoxyverine citrate continue to be marketed.

    Mixtures: Exall D, Zotex-D
  4. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. … [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: PAROXETIN 1A PHARMA 10MG, PAROXETIN 1A PHARMA 20MG
  5. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Gantenerumab binds to a unique Aβ epitope compared to other anti-Aβ antibodies and preferentially recognizes Aβ oligomers and fibrils over monomers.[A244720] … Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary

  6. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  7. Drug

    Muromonab

    go.drugbank.com/drugs/DB00075
    ApprovedInvestigationalWithdrawn

    Muromonab is 93% monomeric immune globulin G type 2a (IgG2a). … More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.

  8. Drug

    Alogliptin

    go.drugbank.com/drugs/DB06203
    ApprovedInvestigational

    FDA approved January 25, 2013. … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4).

  9. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  10. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the … Tegafur (INN, BAN, USAN) is a prodrug of [DB00544] (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers.

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index